Kenvue Inc.
KVUE Large CapConsumer Defensive · Household & Personal Products
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; A
Kenvue Inc. Stock at a Glance
Kenvue Inc. (KVUE) is currently trading at $18.14 with a market capitalization of $34.8B. The trailing P/E ratio stands at 21.6x, with a forward P/E of 14.67x. The 52-week range spans from $14.02 to $22.87; the current price is 20.7% below the yearly high. Year-over-year revenue growth stands at +4.5%. The net profit margin stands at 10.61%.
💰 Dividend
Kenvue Inc. pays an annual dividend of $0.83 per share, representing a yield of 4.58%. The payout ratio stands at 98.51%. The elevated payout ratio reflects a mature dividend policy.
📊 Analyst Rating
12 analysts rate Kenvue Inc. (KVUE) on consensus: None. The average price target is $19.50, implying +7.5% from the current price. Analyst price targets range from $18.00 to $23.00.
Kenvue Inc.: The Investment Case in Detail
Kenvue Inc. (KVUE) operates in the Consumer Defensive — specifically Household & Personal Products — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Earnings growth of 46.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 58.6% gross margin and 21.62% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.
The Bear Case
Revenue growth has slowed to just 4.5%, which is below nominal GDP — the business is no longer outgrowing the broader economy.
What to Watch Next
- The forward P/E of 14.67x is meaningfully below the trailing 21.6x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- High return on equity (15.7% ROE)
- High gross margin of 58.6% — indicates pricing power
- Solid dividend yield of 4.58%
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Consumer Defensive stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Kenvue Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news